BUST FENTANYL Act
- Bill Number
- S. 860
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- International Affairs
- Status
- Introduced
- Latest Action
- 2025-04-28: Placed on Senate Legislative Calendar under General Orders. Calendar No. 54.
- Last Updated
- 2026-02-24T14:10:39Z
AI-Generated Summary
Purpose of the Legislation
The BUST FENTANYL Act (S. 860) aims to strengthen U.S. efforts to combat the trafficking of synthetic opioids, particularly fentanyl, and methamphetamine into the United States. It focuses on improving reporting requirements, enhancing international cooperation, and expanding sanctions against key producers and traffickers, with a strong emphasis on the role of the People's Republic of China (PRC) as a primary source of precursor chemicals and related activities.
Key Provisions
- Modifications to the International Narcotics Control Strategy Report (INCSR): Updates the annual report (under the Foreign Assistance Act of 1961) by shifting its deadline from March 1 to June 1 and revising the section on methamphetamine to focus on chemical precursors that significantly impact the U.S.
- Study and Report on Fentanyl Trafficking: Requires the Secretary of State and Attorney General to submit a report within 180 days of enactment, including unclassified and classified elements. The report covers U.S. efforts to secure PRC commitments on controlling unregulated fentanyl precursors (e.g., 4-AP), plans to combat production and trafficking, assessments of PRC financial involvement in money laundering, evaluations of international coalitions like the Trilateral Fentanyl Committee and Global Coalition to Address Synthetic Drug Threats, and similar analyses for countries like India and Mexico. It also mandates a classified briefing on establishing Drug Enforcement Administration (DEA) offices in Shanghai and Guangzhou, PRC.
- Prioritization of PRC Entities in Sanctions: Amends the Fentanyl Sanctions Act to require the President to prioritize identifying PRC individuals and entities involved in shipping fentanyl-related substances and equipment to Mexico or other production countries. This prioritization ends only after presidential certification that the PRC is no longer the primary source. It extends the reporting deadline to December 31, 2030.
- Expansion of Sanctions: Broadens sanctions under the Fentanyl Sanctions Act to target foreign persons knowingly involved in significant activities or financial transactions contributing to opioid trafficking post-enactment, including those receiving proceeds, providing support, or controlled by such actors.
- Sanctions on Foreign Government Entities: Authorizes the President to impose sanctions on foreign government agencies, subdivisions, or instrumentalities (including state-owned financial institutions) that knowingly support opioid trafficking through activities or transactions. It also allows targeted sanctions on senior officials facilitating such actions.
- Annual Report on Methamphetamine Smuggling from Mexico: Amends the Combat Methamphetamine Epidemic Act of 2005 to require the INCSR to identify major source countries for methamphetamine affecting the U.S. and describe those countries' actions against precursor chemical diversion, production, and trafficking.
Significant Changes to Existing Law
- INCSR Updates: Extends the reporting deadline and refocuses methamphetamine precursor information from specific chemicals (e.g., pseudoephedrine) to those with major U.S. impacts, providing broader flexibility.
- Fentanyl Sanctions Act Amendments: Introduces mandatory prioritization of PRC actors, expands sanctionable activities to include post-enactment opioid trafficking support and financial benefits, and sets a longer-term reporting horizon (to 2030 instead of five years post-enactment). It also enables sanctions on foreign state entities and officials, which were not previously emphasized.
- New Reporting Mandates: Adds detailed, joint reports and briefings on PRC cooperation and international efforts, filling gaps in existing narcotics reporting laws by requiring assessments of financial systems, supply chain shifts, and multilateral progress.
- Methamphetamine Reporting Enhancement: Shifts from a general report to one specifically identifying source countries and their anti-trafficking measures, increasing accountability for international partners.
Potential Impacts
- On Government Agencies: Increases workload for the Departments of State, Justice (including DEA and Attorney General), and the Executive Office in preparing reports, briefings, and implementing sanctions. It may enhance DEA's operational presence abroad if PRC approvals for offices are secured.
- On Citizens: Could reduce fentanyl and methamphetamine availability in the U.S. by disrupting supply chains, potentially lowering overdose deaths and related public health costs, though enforcement challenges may limit immediate effects.
- On International Relations: May strain U.S.-PRC ties due to sanctions prioritization and criticism of PRC financial systems, but could foster cooperation through coalitions with Mexico, Canada, India, and others. It promotes diplomatic pressure on precursor controls, possibly improving global anti-drug efforts but risking retaliatory measures from targeted countries.
Main Stakeholders Affected
- U.S. Government Entities: Departments of State and Justice, DEA, and congressional committees (e.g., Senate Foreign Relations and Judiciary; House Foreign Affairs and Judiciary) responsible for oversight and implementation.
- Foreign Governments and Entities: PRC government, financial institutions, and officials; governments of Mexico, India, and other source countries; participants in international groups like the Trilateral Fentanyl Committee and Global Coalition.
- Private Sector Actors: PRC and foreign pharmaceutical producers, chemical suppliers, money laundering organizations, and financial institutions involved in trafficking support.
- U.S. Citizens and Communities: Those impacted by the opioid crisis, including victims of addiction, law enforcement, and public health providers benefiting from reduced drug inflows.
- International Partners: Countries in East Asia, Southeast Asia, Canada, and Mexico affected by synthetic drug threats.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Expands the executive branch's authority under existing sanctions frameworks (e.g., Fentanyl Sanctions Act) to target state-linked actors without new congressional approval for each action, potentially streamlining enforcement but raising questions about due process for designated entities. Definitions like "knowingly" and "opioid trafficking" align with prior laws, ensuring consistency.
- Constitutional Implications: Relies on the President's foreign affairs powers (Article II) for sanctions and diplomacy, which courts have generally upheld, but could invite challenges if sanctions affect U.S. persons or property without adequate judicial review.
- Political Implications: Signals bipartisan concern over the opioid crisis (introduced by Sens. Risch, Shaheen, Hagerty, and Coons), potentially influencing U.S. foreign policy toward China amid broader tensions. It emphasizes multilateralism but prioritizes unilateral sanctions, which may affect trade negotiations or alliances in narcotics control.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (3)
Sen. Shaheen, Jeanne [D-NH], Sen. Hagerty, Bill [R-TN], Sen. Coons, Christopher A. [D-DE]
Recent Actions
- 2025-04-28: Placed on Senate Legislative Calendar under General Orders. Calendar No. 54.
- 2025-04-28: Committee on Foreign Relations. Reported by Senator Risch without amendment. Without written report.
- 2025-04-28: Committee on Foreign Relations. Reported by Senator Risch without amendment. Without written report.
- 2025-03-27: Committee on Foreign Relations. Ordered to be reported without amendment favorably.
- 2025-03-05: Read twice and referred to the Committee on Foreign Relations.
- 2025-03-05: Introduced in Senate
Bill Versions
- Break Up Suspicious Transactions of Fentanyl Act — issued 2025-03-05 — PDF (12 pages)
- Break Up Suspicious Transactions of Fentanyl Act — issued 2025-04-28 — PDF (14 pages)